85-693: COVID-19 Vaccines Global Access , abbreviated as COVAX , is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), alongside key delivery partner UNICEF . It is one of the four pillars of the Access to COVID-19 Tools Accelerator , an initiative begun in April 2020 by
170-584: A memorandum of understanding (MoU) with Bharat Biotech and announced that the production of Covaxin by them will commence after obtaining support from the Maharashtra state government and approval from the Indian government whereas Indian Immunologicals Limited (IIL) has signed a commercial agreement with Bharat Biotech for producing the drug substance, a critical component of the vaccine Bharat Immunologicals and Biologicals Corporation (BIBCOL) will also manufacture
255-717: A 125-million-dose gap in the COVAX program. Only a limited amount of vaccines are distributed efficiently, and the shortfall of vaccines in South America and parts of Asia are due to a lack of expedient donations by richer nations. International organisations have pointed at Nepal, Sri Lanka, and Maldives as well as Argentina and Brazil, and some parts of the Caribbean as problem areas, where vaccines are in short supply. UNICEF has also been critical towards proposed donations of Moderna and Pfizer vaccines since these are not slated for delivery until
340-503: A COVID‑19 vaccine candidate to boost its immunogenicity and efficacy to reduce or prevent COVID‑19 infection in vaccinated individuals. Adjuvants used in COVID‑;19 vaccine formulation may be particularly effective for technologies using the inactivated COVID‑19 virus and recombinant protein-based or vector-based vaccines. Aluminum salts, known as " alum ", were the first adjuvant used for licensed vaccines and are
425-460: A decade to develop. In contrast, mRNA is a molecule that can be made quickly, and research on mRNA to fight diseases was begun decades before the COVID‑19 pandemic by scientists such as Drew Weissman and Katalin Karikó , who tested on mice. Moderna began human testing of an mRNA vaccine in 2015. Viral vector vaccines were also developed for the COVID‑19 pandemic after the technology
510-483: A joint venture between Sinopharm and Group 42, the country has donated vaccine doses to several African countries. It is possible for private donors to donate to COVAX through the "Go Give One" campaign. The WHO estimates the campaign's cost-effectiveness at one vaccine dose per US$ 7 donated. COVID-19 vaccine A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ),
595-723: A partnership with Bharat Biotech to co-develop and exclusively commercialise Covaxin in the US market; in June 2021, the partnership was extended to cover Canada. In January 2021, Precisa Medicamentos entered into an agreement with Bharat Biotech to supply Covaxin to Brazil. The contract was terminated in July 2021 after the Brazilian government suspended procurement to investigate allegations of irregularities in pricing. In May 2021, Haffkine Bio-Pharmaceutical Corporation Limited of Haffkine Institute entered into
680-623: A response to the COVID-19 pandemic . COVID-19 Vaccines Global Access (COVAX) is one of its four pillars. It is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the WHO, alongside key delivery partner UNICEF . COVAX coordinates international resources to enable low-to-middle-income countries equitable access to COVID-19 tests , therapies , and vaccines . A financing instrument called
765-850: A robust T-cell response and their genes are more conserved and recombine less frequently (compared to Spike). Future generations of COVID‑19 vaccines that may target more conserved genomic regions will also act as insurance against the manifestation of catastrophic scenarios concerning the future evolutionary path of SARS-CoV-2, or any similar coronavirus epidemic/pandemic. Platforms developed in 2020 involved nucleic acid technologies ( nucleoside-modified messenger RNA and DNA ), non-replicating viral vectors , peptides , recombinant proteins , live attenuated viruses , and inactivated viruses . Many vaccine technologies being developed for COVID‑19 are not like influenza vaccines but rather use "next-generation" strategies for precise targeting of COVID‑19 infection mechanisms. Several of
850-474: A second intranasal vaccine as a booster, trade name Pneucolin . Aivita Biomedical is developing an experimental autologous dendritic cell COVID‑19 vaccine kit where the vaccine is prepared and incubated at the point-of-care using cells from the intended recipient. The vaccine is undergoing small phase I and phase II clinical studies. A universal coronavirus vaccine would be effective against all coronaviruses and possibly other viruses. The concept
935-457: A spike ferritin-based nanoparticle (SpFN). This vaccine began a Phase I clinical trial in April 2022. Results of this trial were published in May 2024. Other universal vaccines that have entered clinical trial include OVX033 (France), PanCov (France), pEVAC-PS (UK), and VBI-2902 (Canada). Another strategy is to attach vaccine fragments from multiple strains to a nanoparticle scaffold. One theory
SECTION 10
#17330856815481020-495: Is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval . Effectiveness is generally expected to slowly decrease over time. A phase 3 clinical trial with 25,798 participants found that the vaccine is 64% (95% CI , 29 – 82% ) effective against asymptomatic cases, 78% ( 65 – 86% ) effective against symptomatic disease, 93% ( 57 – 100% ) effective against severe disease, and 65% ( 33 – 83% ) effective against
1105-498: Is that a broader range of strains can be vaccinated against by targeting the receptor-binding domain, rather than the whole spike protein . As of September 2020 , eleven of the vaccine candidates in clinical development use adjuvants to enhance immunogenicity. An immunological adjuvant is a substance formulated with a vaccine to elevate the immune response to an antigen , such as the COVID‑19 virus or influenza virus. Specifically, an adjuvant may be used in formulating
1190-641: Is the same as Convidecia's only dose. In August 2021, the developers of Sputnik V proposed, in view of the Delta case surge, that Pfizer test the Ad26 component (termed its 'Light' version) as a booster shot. Inactivated vaccines consist of virus particles that are grown in culture and then killed using a method such as heat or formaldehyde to lose disease-producing capacity while still stimulating an immune response. Inactivated virus vaccines authorized in China include
1275-510: Is under trials. In May 2021, Drugs Controller General of India (DCGI) approved clinical trials in the age group of 2 to 18 years. The trials are conducted at AIIMS Delhi and Patna. As many as 54 children had registered at the AIIMS Patna . In total 525 participants are enrolled in the study as per clinical trial data. In December 2020, the Alpha variant or lineage B.1.1.7, was identified in
1360-540: The AstraZeneca vaccine through the program, but Venezuelan health officials did not approve the product for domestic use. According to a report produced by the People's Vaccine Alliance covering 14 countries, ' vaccine hesitancy ' was not the reason for low jab rates in low- and middle-income countries. But the report found that a lack of testing capacity, sufficient vaccine doses and refrigerated storage were mostly to blame for
1445-570: The Delta variant . As an inactivated vaccine , Covaxin uses a more traditional technology that is similar to the inactivated polio vaccine . Initially, a sample of SARS-CoV-2 was isolated by India's National Institute of Virology and used to grow large quantities of the virus using vero cells . From then on, the viruses are soaked in beta-propiolactone (BPL), which deactivates them by binding to their genes, while leaving other viral particles intact. The resulting inactivated viruses are then mixed with
1530-496: The European Investment Bank , provided free vaccinations to individuals in the world's 92 poorest countries. So far, more than 1.6 billion COVAX doses have been provided to poor nations, assisting in the vaccination of 52% of their population, compared to a global average of 64%. The United Kingdom has provided £548 million to Covax. The United Kingdom was the biggest single donor to COVAX-AMC until being overtaken by
1615-608: The Foreign Office of the Federal Republic of Germany, Germany has joined COVAX through the European Union and has pledged €300 million for the treatment of COVID-19 in developing nations bringing the total EU contribution to over €2.2 billion. On the consilium site, Team Europe reported a €2.47 billion donation. The Gavi COVAX Advance Market Commitment, a financing mechanism supported by donors and expedited by
1700-587: The Oxford–AstraZeneca COVID‑19 vaccine , the Sputnik V COVID‑19 vaccine , Convidecia , and the Janssen COVID‑19 vaccine . Convidecia and Janssen are both one-shot vaccines that offer less complicated logistics and can be stored under ordinary refrigeration for several months. Sputnik V uses Ad26 for its first dose, which is the same as Janssen's only dose, and Ad5 for the second dose, which
1785-653: The Oxford–AstraZeneca vaccine , up to 700 million doses were expected for 2021. After initial deliveries to North Africa, West Africa, Eastern Europe and the Middle East in March and April 2021, India began to limit vaccine exports until the end of 2021, due to high domestic demand. Based on the high infection rates in India, COVAX was projected to deliver only 145 million doses instead of 240 million by May 2021. Vaccine production
SECTION 20
#17330856815481870-557: The Serum Institute of India (SII), for domestic use in India. As of April 2022, more than 1.4 billion doses were delivered, when the largest recipients were Bangladesh (183 million doses), Pakistan (112 million) and Indonesia (104 million). In April 2020 the World Health Organization (WHO), the European Commission , and the government of France founded the Access to COVID-19 Tools Accelerator , an initiative begun as
1955-413: The nasal mucosa , which is a portal for viral entry into the body. These vaccines are designed to stimulate nasal immune factors , such as IgA . In addition to inhibiting the virus, nasal vaccines provide ease of administration because no needles (or needle phobia ) are involved. A variety of intranasal COVID‑19 vaccines are undergoing clinical trials. The first authorised intranasal vaccine
2040-649: The COVAX mechanism through the COVAX Vaccines Advance Market Commitment (AMC) financing instrument. COVAX AMC is funded by donor contributions. COVAX AMC funds the COVAX Facility , the vaccine procurement platform. On 3 February 2021, GAVI, the WHO, and UNICEF published the country-by-country distribution of the Pfizer–BioNTech and Oxford–AstraZeneca vaccines forecast for first half of 2021. The early projection includes 336 million doses of
2125-557: The COVAX program. Almost 800,000 individuals or 52% of the adult population received two doses of the CoronaVac or Pfizer vaccines. The government also studied the effectiveness of the Pfizer/BioNTech vaccine among 162,047 health workers and people over 80 years old. Both vaccine types reduced hospitalisations and deaths by over 90%, and infection rates by more than 60%. Because of accessible healthcare and available COVAX vaccine supplies,
2210-584: The COVID-19 Vaccines Advance Market Commitment (COVAX AMC) was presented to prospective donors at the Gavi COVAX AMC 2021 Investment Opportunity Launch Event, otherwise named One World Protected, on 15 April 2021. The virtual event was hosted by GAVI board chair José Manuel Barroso , U.S. Secretary of State Antony Blinken , and acting United States Agency for International Development (USAID) Administrator Gloria Steele . Among
2295-882: The Chinese CoronaVac and the Sinopharm BIBP and WIBP vaccines; there is also the Indian Covaxin , the Russian CoviVac , the Kazakh vaccine QazVac , and the Iranian COVIran Barekat . Vaccines in clinical trials include the Valneva COVID‑;19 vaccine . Subunit vaccines present one or more antigens without introducing whole pathogen particles. The antigens involved are often protein subunits , but they can be any molecule fragment of
2380-536: The EU into COVAX on 31 August 2020 and pledged €400 million in guarantees , but did not state how this money would be paid out or its conditions. The EC pledged a further €100 million from the 11th European Development Fund to COVAX via a grant to GAVI on 12 November. Individual EU member states have also made additional pledges; France donated an additional €100 million, Spain an additional €50 million, and Finland an additional €2 million. According to
2465-617: The European Union and the United States. As part of its America First policy , the Trump administration stated that it would not join COVAX because of its association with the WHO, from which it had begun a year-long withdrawal process on 6 July 2020. After Joe Biden was elected president in the 2020 election , he announced that the United States would remain in the WHO and would join COVAX on 20 January 2021. This reversal of American policy (announced by Anthony Fauci , Chief Medical Advisor to
2550-716: The European Union. Authorized vaccines of this type include the Pfizer–BioNTech and Moderna vaccines. The CVnCoV RNA vaccine from CureVac failed in clinical trials. Severe allergic reactions are rare. In December 2020, 1,893,360 first doses of Pfizer–BioNTech COVID‑19 vaccine administration resulted in 175 cases of severe allergic reactions, of which 21 were anaphylaxis . For 4,041,396 Moderna COVID‑19 vaccine dose administrations in December 2020 and January 2021, only ten cases of anaphylaxis were reported. Lipid nanoparticles (LNPs) were most likely responsible for
2635-627: The Ivory Coast became the first persons to be inoculated with COVID-19 vaccines shipped from the COVAX Facility. More than 500,000 doses of the Oxford–AstraZeneca COVID-19 vaccine manufactured by the Serum Institute of India were shipped to the city of Abidjan the week before. The vaccines were flown in by UNICEF from Mumbai . On 5 March 2021, Moldova received 14,400 Oxford–AstraZeneca COVID-19 vaccine units through COVAX, becoming
COVAX - Misplaced Pages Continue
2720-619: The Johnson & Johnson COVID-19 vaccine, providing a total of 620 million doses to Africa by the end of 2021. The vaccines will be in part sourced from licensed production in South Africa, and distributed by COVAX with the goal to vaccinate 60% of the population. Since the UAE started producing Hayat-Vax in late March 2021, a rebranded version of the Chinese Sinopharm BIBP vaccine through
2805-483: The Oxford–AstraZeneca vaccine as well as 1.2 million doses of the Pfizer–BioNTech vaccine to the 145 COVAX facility participants. It is expected that health care workers and the most vulnerable will receive the first doses, which are anticipated to reach approximately 3.3% of the total population of each participating country by the end of the first half of 2021. In February 2021, the WHO and Chubb Limited announced
2890-606: The President ) was welcomed globally. On 19 February, the US pledged $ 4 billion, making it the single largest contributor to the fund. On 16 July 2021, the African Union (AU)/African Vaccine Acquisition Trust (AVAT), COVAX and the United States government announced the donation of 25 million Johnson & Johnson COVID-19 vaccines to 49 African countries. Afreximbank put in place a US$ 2 billion Advance Procurement Commitment (APC) Guarantee to obtain 400 million more doses of
2975-595: The UK. An in vitro study on this variant was carried out and preliminary results show Covaxin to be effective in neutralising this strain. In April 2021, the Indian Council of Medical Research reported that the vaccine has shown promising results in neutralising lineage B.1.617 . In May 2021, a joint investigation by the scientists of the National Institute of Virology , found the vaccine effective in neutralising
3060-498: The United States beginning in fall 2024 should be monovalent JN.1 vaccines. Since January 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. Multiple steps along the entire development path are evaluated, including: There have been several unique challenges with COVID‑19 vaccine development. Public health programs have been described as "[a] race to vaccinate individuals" with
3145-511: The WHO for distribution through COVAX. By July 2021, GAVI had signed advanced purchase agreements for 170 million doses of the Sinopharm BIBP vaccine, 350 million doses of CoronaVac, and 414 million doses of SCB-2019 , another vaccine in Phase III trials. On 8 August 2021, China pledges US$ 100 million towards equitable access to COVID-19 vaccines for lower-income countries, brings
3230-698: The WHO, the European Commission , and the government of France as a response to the COVID-19 pandemic . COVAX coordinates international resources to enable low-to-middle-income countries equitable access to COVID-19 tests , therapies , and vaccines . UNICEF is the key delivery partner, leveraging its experience as the largest single vaccine buyer in the world and working on the procurement of COVID-19 vaccine doses, as well as logistics, country readiness and in-country delivery. By 19 October 2020, 184 countries had joined COVAX. COVAX began distributing vaccines in February 2021. Though COVAX promised 100 million doses by
3315-571: The Zeta variant or lineage P.2 (previously known as B.1.1.28). In June 2021, a group of researchers at the National Institute of Virology (NIV) India, collected sera from recovered patients and people who had received the Covaxin. They found the vaccine to be effective in neutralising the Delta ( B.1.617.2 ) and Beta ( B.1.351 ) variants. Later, the US National Institute of Health also approved
3400-504: The adjuvant of choice in some 80% of adjuvanted vaccines. The alum adjuvant initiates diverse molecular and cellular mechanisms to enhance immunogenicity, including the release of proinflammatory cytokines. In June 2024, the US Food and Drug Administration (FDA) advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in
3485-430: The allergic reactions. These vaccines are examples of non-replicating viral vector vaccines using an adenovirus shell containing DNA that encodes a SARS‑CoV‑2 protein. The viral vector-based vaccines against COVID‑19 are non-replicating, meaning that they do not make new virus particles but rather produce only the antigen that elicits a systemic immune response. Authorized vaccines of this type include
COVAX - Misplaced Pages Continue
3570-703: The aluminium-based adjuvant Alhydroxiquim-II. The vaccine is produced with Bharat Biotech's in-house vero cell manufacturing platform that has the capacity to deliver about 300 million doses. The company is in the process of setting up a second plant at its Genome Valley facility in Hyderabad to make Covaxin. The firm, in collaboration with the Government of Odisha , is establishing another facility at Odisha Biotech Park in Bhubaneswar to commence Covaxin production by June 2022. In December 2020, Ocugen entered into
3655-442: The approval to conduct Phase III human trials after completion of Phase I and II. A randomised, double-blinded, placebo-controlled study among volunteers of age group 18 and above, it started on 25 November and involved around 26,000 volunteers from across 22 sites in India. Refusal rate for Phase III trials was much higher than that for Phase I and Phase II. As a result, only 13,000 volunteers had been recruited by 22 December with
3740-538: The attendees were heads of state, corporate leaders and representatives from global nonprofit organizations. The program was fully launched by GAVI at the Global Vaccine Summit on 4 June 2021. As of 23 December 2021, the WHO had approved Oxford–AstraZeneca , Pfizer–BioNTech , Moderna , Sinopharm BIBP , CoronaVac , Janssen , Covaxin , and Novavax vaccines for emergency use. These vaccines can be distributed as part of COVAX per decision in May 2021. Many of
3825-518: The body how to identify and destroy the corresponding pathogen. RNA vaccines often use nucleoside-modified messenger RNA . The delivery of mRNA is achieved by a coformulation of the molecule into lipid nanoparticles , which protect the RNA strands and help their absorption into the cells. RNA vaccines are the first COVID‑19 vaccines to be authorized in the United Kingdom, the United States, and
3910-496: The brand name Comirnaty. On 24 August 2020 WHO stated that COVAX had nine CEPI-supported vaccine candidates and nine candidates undergoing trials, giving it the largest selection of COVID-19 vaccinations in the world. By December 2020, COVAX had finalized negotiations with other manufacturers that gave it access to two billion vaccine doses. COVAX provides vaccines to the developing world . A total of 92 low- and middle-income countries are eligible to receive COVID-19 vaccines through
3995-688: The company published Phase I trial results in The Lancet . On 8 March 2021, Phase II results were published in The Lancet . The study showed that Phase II trials had a higher immune response and induced T-cell response due to the difference in dosing regime from Phase I. The doses in Phase II were given at 4 weeks interval as opposed to 2 weeks in Phase I. Neutralization response of the vaccine were found significantly higher in Phase II. In November 2020, Covaxin received
4080-484: The company received permission to conduct Phase I and Phase II human trials of a developmental COVID-19 vaccine codenamed BBV152 , from the Drugs Controller General of India ( DCGI ), Government of India . A total of 12 sites were selected by the Indian Council for Medical Research for Phase I and II randomised, double-blind and placebo-controlled clinical trials of vaccine candidate. In January 2021,
4165-603: The countries benefitting from COVAX have "limited regulatory capacity" and depend on WHO's authorisations. By early 2021, WHO was reviewing 11 potential COVID-19 vaccines for its Emergency Use Listing (EUL). The first vaccine WHO authorised for its EUL on 31 December 2020 was the Pfizer–BioNTech COVID-19 vaccine —an RNA vaccine developed by the German company BioNTech in cooperation with the American company Pfizer sold under
4250-414: The country due to non-compliance with manufacturing norms. Bharat Biotech stated that they would re-apply after meeting the requirements. On 4 June, Anvisa approved exceptional imports of Covaxin, imposing conditions that restrict it mainly to healthy adults and limiting it to just 1% of the country's population to manage the risks through control and supervision of side effects. Anvisa cited as main concerns
4335-495: The doses purchased by high-income countries comprising 14% of the world's population. Despite the extremely rapid development of effective mRNA and viral vector vaccines , worldwide vaccine equity has not been achieved. The development and use of whole inactivated virus (WIV) and protein-based vaccines have also been recommended, especially for use in developing countries . The 2023 Nobel Prize in Physiology or Medicine
SECTION 50
#17330856815484420-579: The early wave vaccines. Covaxin Covaxin ( development name , BBV152 ) is a whole inactivated virus -based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology . On 3 November 2021, the World Health Organization (WHO) validated the vaccine for emergency use, as the first Indian-developed covid vaccine to be approved. By 31 January 2022, Covaxin had been granted emergency use approval in 13 countries. A vaccine
4505-735: The elderly, and those at high risk of exposure and transmission, such as healthcare workers. Common side effects of COVID‑19 vaccines include soreness, redness, rash, inflammation at the injection site, fatigue, headache, myalgia (muscle pain), and arthralgia (joint pain), which resolve without medical treatment within a few days. COVID‑19 vaccination is safe for people who are pregnant or are breastfeeding. As of 12 August 2024 , 13.72 billion doses of COVID‑19 vaccines have been administered worldwide, based on official reports from national public health agencies . By December 2020, more than 10 billion vaccine doses had been preordered by countries, with about half of
4590-464: The elderly, children, pregnant women , and people with weakened immune systems . Several COVID‑19 vaccines, such as the Pfizer–BioNTech and Moderna vaccines, use RNA to stimulate an immune response. When introduced into human tissue, the vaccine contains either self-replicating RNA or messenger RNA (mRNA), which both cause cells to express the SARS-CoV-2 spike protein . This teaches
4675-430: The end of March, this goal was not reached until 6 July. By mid-August 2021, COVAX delivered 200 million vaccine doses to nearly 140 countries instead of the 600 million doses initially projected. The continued shortage of COVID-19 vaccines delivered through COVAX is blamed on "vaccine nationalism" by richer nations, and the diversion of 400 million Oxford–AstraZeneca COVID-19 vaccine doses, produced under license by
4760-429: The family Coronaviridae that affect humans have been aimed at severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Vaccines against SARS and MERS have been tested in non-human animals . According to studies published in 2005 and 2006, the identification and development of novel vaccines and medicines to treat SARS was a priority for governments and public health agencies around
4845-582: The findings where the adjuvant used was developed jointly with funding from NIH . On 6 December 2020, Bharat Biotech applied to the Drugs Controller General of India (DCGI), seeking emergency use authorisation. It was the third firm after Serum Institute of India and Pfizer to apply under such provision. On 2 January 2021, the Central Drugs Standard Control Organisation (CDSCO) recommended permission, which
4930-555: The first European country to do so. The country had already been donated 21,600 doses of the same vaccine by Romania some days earlier. On 25 March 2021, Bosnia and Herzegovina received 24,300 Pfizer–BioNTech and 26,400 Oxford–AstraZeneca COVID-19 vaccine units through COVAX, becoming the second European country to do so. The country had already been, in total, donated over 20,000 doses of the Oxford–AstraZeneca vaccine by Serbia and Slovenia some weeks earlier. On 8 June 2021, Uruguay released health data from their vaccination efforts through
5015-513: The immune system and lessen the severity of COVID‑19 infections. There is experimental evidence that the BCG vaccine for tuberculosis has non-specific effects on the immune system, but there is no evidence that this vaccine is effective against COVID‑19. Most coronavirus vaccines are administered by injection, with further vaccine delivery methods being studied for future coronavirus vaccines. Intranasal vaccines target mucosal immunity in
5100-429: The incomplete phase III study, a short 45-day follow-up, which should be 60 days to meet the international consensus, and a novel imidazoquinoline adjuvant that may increase the chance of developing an autoimmune disease. On 30 June, Brazilian regulators suspended the deal and an investigation was opened into it by federal prosecutors to probe accusations of irregularity. Anvisa cancelled an ongoing clinical trial of
5185-593: The individual member states). Although more than $ 6 billion was pledged, not all of the funding has been delivered yet. In April, the initiative wrote that it had not yet received its target of $ 3.2 billion for 2021. Although mainly funded by governments (" Official Development Assistance "), the COVAX scheme is also funded by private-sector and philanthropic contributions, and recipient countries may share some costs for vaccines and delivery. In May 2021, UNICEF made an urgent appeal to industrialised nations to pool their excess COVID-19 vaccine capacity to make up for
SECTION 60
#17330856815485270-416: The low vaccination rates. Poor information policies on vaccine distribution and underfunded healthcare systems were also mentioned. The Vaccine Alliance found that "systemic racism has plagued the global response to Covid-19". COVAX is principally funded by Western countries. As of 19 February 2021, 30 countries have signed commitment agreements to the COVAX Facility as well as the European Union (apart from
5355-415: The number increasing to 23,000 by 5 January. Multiple ethical breaches have been reported at one of their trial sites in Bhopal , potentially hampering the quality of overall data. In March 2022, Ocugen registered a Phase 2/3 trial for 400 people in the US to compare the immune responses to those in people in the Indian phase 3 trial, as well as safety and tolerability. The trial also aims to assess
5440-412: The pathogen. The authorized vaccines of this type include the peptide vaccine EpiVacCorona , ZF2001 , MVC-COV1901 , Corbevax , the Sanofi–GSK vaccine , and Soberana 02 (a conjugate vaccine ). Bimervax (selvacovatein) was approved for use as a booster vaccine in the European Union in March 2023. The V451 vaccine was in clinical trials that were terminated after it was found that
5525-399: The platforms of vaccine candidates in clinical trials are focused on the coronavirus spike protein (S protein) and its variants as the primary antigen of COVID‑19 infection, since the S protein triggers strong B-cell and T-cell immune responses. However, other coronavirus proteins are also being investigated for vaccine development, like the nucleocapsid , because they also induce
5610-598: The roll out of a no-fault compensation scheme for COVID-19 vaccinations for low and middle-income countries which would be financed initially through Gavi COVAX AMC donor funding. On 24 February 2021, Ghana became the first country in the world to receive vaccines through COVAX when 600,000 doses of the Oxford–AstraZeneca vaccine were delivered to Accra . On 2 March, COVID-19 vaccines were being distributed in Ghana by Zipline drones. This method allows reaching remote areas (which are underserved by traditional logistics). On 1 March 2021, frontline workers and public officials from
5695-554: The second half of 2021, or early 2022. Canada pledged $ 220 million worth of vaccines on 25 September 2020 to join as a self-financing contributor to COVAX. On 14 June, Canada doubled its pledge to add an additional 13 million doses of AstraZeneca, Johnson & Johnson, and NovaVax vaccines. This was in addition to the over 80 million available to purchase through financial contribution. China joined COVAX on 9 October 2020. The Sinopharm BIBP vaccine and CoronaVac (by Sinovac Biotech ) are Chinese-developed vaccines approved by
5780-539: The small Latin nation was able to ward off a serious COVID-19 spike in May 2021. On 1 August 2021, the Venezuelan government announced it will receive 6.2 million doses of coronavirus vaccines through the COVAX initiative. Part of the payment to the GAVI alliance was first blocked due to economic sanctions . Venezuela is a self-financing participant of COVAX. According to the Pan-American Health Organization (PAHO), Venezuela will receive China's Sinopharm BIBP vaccine and CoronaVac . The country previously obtained
5865-413: The synthetic vaccines use a 2P mutation to lock the spike protein into its prefusion configuration, stimulating an adaptive immune response to the virus before it attaches to a human cell. Vaccine platforms in development may improve flexibility for antigen manipulation and effectiveness for targeting mechanisms of COVID‑19 infection in susceptible population subgroups, such as healthcare workers,
5950-415: The total raised for the Covax to nearly US$ 10 billion Further, China's Leader Xi Jinping pledges 2 billion vaccines globally through year's end. According to AP News, China has already delivered 770 million doses to foreign countries since September 2020 (as of 6 August 2021) India joined COVAX through a membership with the GAVI alliance. The Serum Institute of India is the main producer for
6035-410: The vaccine as a booster after other Covid vaccines used in the US. Ocugen paused Covaxin's bridging trial in April 2022 citing WHO inspection results. In June 2021, Bharat Biotech announced the start of phase IV trials to evaluate the vaccine's real-world effectiveness. A study of effectiveness and hesitancy study in Healthcare Workers of Max Group of Hospitals at New Delhi from Covaxin and Covishied
6120-615: The vaccine may potentially cause incorrect results for subsequent HIV testing. The authorized vaccines of this type include the Novavax COVID‑19 vaccine . Additional types of vaccines that are in clinical trials include multiple DNA plasmid vaccines , at least two lentivirus vector vaccines, a conjugate vaccine , and a vesicular stomatitis virus displaying the SARS‑CoV‑2 spike protein. Scientists investigated whether existing vaccines for unrelated conditions could prime
6205-439: The vaccine on 26 July and suspended the temporary authorization and the import and distribution permit on 27 July. Mauritius received its first commercial supply of Covaxin on 18 March 2021. On 29 March 2021, Paraguay received 100,000 doses of Covaxin. In June 2021, Argentina agreed to buy 10 million doses of Covaxin and administer them to its citizens. On 3 November 2021, the World Health Organization (WHO) validated
6290-467: The vaccine. On 1 April 2022, Bharat Biotech announced that it was cutting production due to reduction in demand. On 2 April the WHO said that a March 2022 inspection of facilities used to manufacture Covaxin had uncovered good manufacturing practice deficiencies. In May 2020, Indian Council of Medical Research's ( ICMR 's) National Institute of Virology approved and provided the virus strains for developing an Indian COVID-19 vaccine. In June 2020,
6375-625: The vaccines has been found to wane over time, requiring people to get booster doses of the vaccine to maintain protection against COVID‑19. The COVID‑19 vaccines are widely credited for their role in reducing the spread of COVID‑19 and reducing the severity and death caused by COVID‑19. According to a June 2022 study, COVID‑19 vaccines prevented an additional 14.4 to 19.8 million deaths in 185 countries and territories from 8 December 2020 to 8 December 2021. Many countries implemented phased distribution plans that prioritized those at highest risk of complications, such as
6460-487: The virus that causes coronavirus disease 2019 ( COVID‑19 ). Before the COVID‑19 pandemic , an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome ( SARS ) and Middle East respiratory syndrome ( MERS ). This knowledge accelerated the development of various vaccine platforms in early 2020. The initial focus of SARS-CoV-2 vaccines
6545-720: The world at that time. There is no cure or protective vaccine proven to be safe and effective against SARS in humans. There is also no proven vaccine against MERS. When MERS became prevalent, it was believed that existing SARS research might provide a useful template for developing vaccines and therapeutics against a MERS-CoV infection. As of March 2020, there was one (DNA-based) MERS vaccine that completed Phase I clinical trials in humans, and three others in progress, all being viral-vectored vaccines: two adenoviral-vectored (ChAdOx1-MERS, BVRS-GamVac) and one MVA -vectored (MVA-MERS-S). Vaccines that use an inactive or weakened virus that has been grown in eggs typically take more than
6630-497: Was Razi Cov Pars in Iran at the end of October 2021. The first viral component of Sputnik V vaccine was authorised in Russia as Sputnik Nasal in April 2022. In September 2022, India and China approved two nasal COVID‑19 vaccines ( iNCOVACC and Convidecia ), which may (as boosters) also reduce transmission (potentially via sterilizing immunity). In December 2022, China approved
6715-549: Was also approved for emergency use in Iran and Zimbabwe. Nepal granted EUA for Covaxin on 19 March 2021. On 7 April, Mexico granted emergency authorisation for Covaxin. On 19 April 2021, Philippines granted EUA to Covaxin. Additionally, Covaxin was granted EUA in Guatemala, Nicaragua, Guyana, Venezuela and Botswana. On 31 March, the Brazilian health regulator Anvisa rejected Bharat Biotech's application for supplying Covaxin in
6800-543: Was also negatively affected because of a ban by the U.S. on the export of key raw materials. In September 2021, the Government of India announced the resumption of vaccines exports from October 2021 onwards since it had quadrupled its production and only excess supplies would be exported. As of November 2020, the European Union (EU) and EU members have pledged €870 million to COVAX. The European Commission (EC) brought
6885-586: Was awarded to Katalin Karikó and Drew Weissman for the development of effective mRNA vaccines against COVID-19. Prior to COVID‑19, a vaccine for an infectious disease had never been produced in less than several years – and no vaccine existed for preventing a coronavirus infection in humans. However, vaccines have been produced against several animal diseases caused by coronaviruses, including (as of 2003) infectious bronchitis virus in birds, canine coronavirus , and feline coronavirus . Previous projects to develop vaccines for viruses in
6970-435: Was granted the next day. Covaxin was to be used in a "clinical trial mode" i.e. the public vaccination drive was to be an open-label, single-arm clinical trial in itself. This emergency approval, granted without considering Phase III trial data concerning efficacy and safety, drew widespread criticism. On 12 October 2021, Bharat Biotech's Covaxin got approved for usage on children between 2 and 18 years of age. The vaccine
7055-462: Was on preventing symptomatic, often severe, illness. In 2020, the first COVID‑19 vaccines were developed and made available to the public through emergency authorizations and conditional approvals. Initially, most COVID‑19 vaccines were two-dose vaccines, with the exception single-dose vaccines Convidecia and the Janssen COVID‑19 vaccine , and vaccines with three-dose schedules, Razi Cov Pars and Soberana . However, immunity from
7140-491: Was previously cleared for Ebola. As multiple COVID‑19 vaccines have been authorized or licensed for use, real-world vaccine effectiveness (RWE) is being assessed using case control and observational studies. A study is investigating the long-lasting protection against SARS-CoV-2 provided by the mRNA vaccines. As of July 2021, at least nine different technology platforms were under research and development to create an effective vaccine against COVID‑19. Most of
7225-525: Was publicly endorsed by NIAID director Anthony Fauci , virologist Jeffery K. Taubenberger , and David M. Morens. In March 2022, the White House released the "National COVID‑19 Preparedness Plan", which recommended accelerating the development of a universal coronavirus vaccine. One attempt at such a vaccine is being developed at the Walter Reed Army Institute of Research . It uses
#547452